Analyst Research Report Snapshot

Title:

ZELTIA - CHARTING A COURSE INTO CLEARER WATERS

Price:

$10.00

Provider:

Edison Investment Research

Date:

07 Mar 2014

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ZEL.MC

Available for Immediate Download
Summary:

Zeltia has made significant progress in weathering the storms of recent years. FY13 results demonstrate improved profitability and cash flows, which have further reduced the debt burden. Ex-US ex-Japan Yondelis sales have resumed their growth trajectory (net revenues up 10% to €73m) following the resolution of Doxil supply issues in May. Looking forward, clinical data in H214 for Zeltia’s two key products could be transformative. Janssen’s 2015 FDA filing of Yondelis rests on positive Phase III sarcoma results, while Taiho could file in Japan by year-end on the back of its pivotal Phase II study. Full data from the Phase II PM01183 study in ovarian cancer could form the basis of a lucrative licensing deal.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.